Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines

Anti-Cancer Drugs

Volumn 15, Issue 1, 2004, Pages 63-70

  Hovstadius, Peter ^a,d   Lindhagen, Elin ^a   Hassan, Sadia ^a   Nilsson, Kenneth ^b   Jernberg Wiklund, Helena ^b   Nygren, Peter ^a   Binderup, Lise ^c   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LEO PHARMA A S   (Denmark)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CHS 828; Cytotoxicity assay; Fluorometric microculture cytotoxicity assay; Hollow fiber model; Myeloma cell line

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GUANIDINE DERIVATIVE; MELPHALAN; N (6 CHLOROPHENOXYHEXYL) N'' CYANO N'' 4 PYRIDYLGUANIDINE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYANIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROMETRY; GUANIDINES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4344630823     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200401000-00010     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999 [see Comments]. CA Cancer J Clin 1999; 49:8-31.
2. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An Overview of 6,633 Patients from 27 Randomized trials. J Clin Oncol 1998; 16:3832-3842.
3. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334-342.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-97.
5. Fridborg H, Jonsson B, Nygren P, Csoka K, Nilsson K, Öberg G, et al. Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br J Cancer 1994; 70:11-17.
6. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999; 35:424-432.
7. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 1996; 74:888-896.
8. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995; 57:131-141.
9. Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Nygren P, Kristensen J, et al. In vivo activity of CHS 828 on hollow-fiber cultures of primary human tumour cells from patients. Cancer Lett 2001; 162:193-200.
10. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
11. Schou C, Ottosen ER, Björkling F, Latini S, Hjarnaa PV, Bramm E, et al. Novel cyanoguanidines with potent oral antitumour activity. Bioorg Med Chem Lett 1997; 7:3095-3100.
12. Åleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander B, et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 2001; 12:821-827.
13. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999; 59:5751-5757.
14. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, et al. A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002; 8:2843-2850.
15. Ravaud A, Morant R, Skov T, Uiters J, Nguyen B. An EORTC/ECSG phase I study of CHS 828, a cyanoguanidine in patients with refractory solid tumors. Proc Am Ass Cancer Res 2001; 42:542.
16. Jemberg-Wiklund H, Nilsson K. Plasma cell and myeloma cell lines. In: Masters JRW, Palsson B (editors): Human Cell Culture. Dordrecht: Kluwer; 2000: III, pp. 81-155.
17. Spets H, Jernberg-Wiklund H, Sambade C, Söderberg O, Nilsson K. The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol 1997; 98:126-133.
18. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50:177-185.
19. Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, et al. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fiber model in rats. Cancer Chemother Pharmacol 2000; 46:493-500.
20. Motulsky H. Grubbs' test for detecting outliers. GraphPad Insight 1997.
21. Martinsson P, de la Torre M, Binderup L, Nygren P, Larsson R. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol 2001; 417:181-187.
22. Ekelund S, Sjöholm A, Nygren P, Binderup L, Larsson R. Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone). Eur J Pharmacol 2001; 418:39-45.
23. Kaiser U, Oldenburg M, Jaques G, Auerbach B, Havemann K. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma. Ann Hematol 1996; 73:121-126.
24. Feinman R, Sawyer J, Hardin J, Tricot G. Cytogenetics and molecular genetics in multiple myeloma. Hematol Oncol Clin North Am 1997; 11:1-25.